Medicenna Reports First Quarter Fiscal 2022 Financial Results and Operational Highlights
— Phase 1/2 ABILITY Study of MDNA11 in patients with advanced solid tumors remains on track for initiation in the third quarter of calendar 2021
United States United Kingdom Elizabeth Williams Superkine Immunotherapies Mann Muhsin Human Research Ethics Committee
Source: leaderpost.com